Martin Bergstrand, Ph.D.

Principal Consultant & MIDD Platform Scientific Lead


  • Co-founded Pharmetheus in 2012, actively working in client projects and with continuous improvements.
  • Expertise includes trial design, pharmacometrics (especially complex pharmacokinetics, mechanism based PKPD and Markov models), and model informed drug development in therapeutic areas such as infectious, metabolic, and cardiovascular diseases.
  • Experience as part-time Researcher at Uppsala University, Sweden, where he performed pharmacometric research primarily by supervision of Ph.D. students. Previously, he worked as Visiting Scientist at Mahidol-Oxford Tropical Medicine Research Unit, Thailand, and Clinical Pharmacology Scientist at AstraZeneca R&D Mölndal, Sweden.
  • M.Sc. in Biomedicine (2003) from University of Kalmar, Sweden, and Ph.D. in Pharmaceutical Biosciences (2011) from Uppsala University, Sweden.
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Concentration-QTcF Analysis of Quizartinib in Patients With Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)Exploring the relationship between BI 456906 exposure and change in fasting plasma glucose, fasting serum insulin, and glycated hemoglobin (HbA1c) using population PKPD modelingModel-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modelingTowards Industrialisation of Probability of Pharmacological Success (PoPS)Application relevant shrinkage metricsCaplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura [2]Pharmacokinetic Modeling and Simulation Support for Age‐ and Weight‐Adjusted Dosing of Dabigatran Etexilate in Children with Venous ThromboembolismCaplacizumab Model-Based Dosing Recommendations In Pediatric Patients With Acquired Thrombotic Thrombocytopenic PurpuraEffect of Plasma Exchange on the Pharmacokinetics and Pharmacodynamics of Caplacizumab, PS1487Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients with Acquired Thrombotic Thrombocytopenic Purpura, PB2249Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling